- Congresos
- IMCAS Americas - abril 2025
- IMCAS Asia - junio 2025
- IMCAS China - julio 2025
- IMCAS World Congress - enero 2026
- Masterclases
- IMCAS India - noviembre 2025
- Congresos
- IMCAS Americas - abril 2025
- IMCAS Asia - junio 2025
- IMCAS China - julio 2025
- IMCAS World Congress - enero 2026
- Masterclases
- IMCAS India - noviembre 2025

IMCAS Academy

Inscribirse

Conectarse

Presentación
Programa
Oradores
Listado de sponsors
Mapa del congreso
Acreditación

VOLVER

IMCAS World Congress 2025
Programa

Adapte el horario de la clase / congreso transmitido en vivo a su zona horaria

Referencia de zona horaria: (UTC+02:00) Europe, Paris

Zona horaria

Zona horaria:Cambiar zona horaria

If you are logged in, change your default time zone in your account

BIA diseases: Myth or reality

Sala: Room 242 - Level 2
Fecha: jueves 30 enero 2025 de 16:00 a 17:00
Formato: SESIÓN ENFOCADA > presentación que cubre una temática principal del congreso

Moderadores

Dr Nathalie BRICOUT

Cirujano Plástico

Francia

Dr Sebastien GARSON

Cirujano Plástico

Francia

Dr Bouraoui KOTTI

Cirujano Plástico

Emiratos Arabes Unidos

Las presentaciones

Horas	Oradores	Título de la presentación	Resumen	Número
16:00	Dr Melinda HAWS	Current status of BIA-ALCL, BIA-SCC, and BII in the US	Ver	140147
16:14	Dr Cole HOLAN	Analyzing sentiment of breast implant illness on social media with natural language processing and deep learning	Ver	144164
16:28	Dr Isabelle PLUVY	Breast implant silicone exposure induces immunogenic response and autoimmune markers in human periprosthetic tissue	Ver	145145
16:42		Discussion and Q&A		140153

Ver sesiones anteriores

Ver la siguiente sesión

Sesiones recomendadas

Implantes de mamas

Aumento de mamas

Cáncer de mamas y reconstrucción

Dr Melinda HAWS

Cirujano Plástico

Estados Unidos

Otro(s) autor(es) : Includes review of papers published by Caroline Glicksman MD and Pat McGuire MD

Current status of BIA-ALCL, BIA-SCC, and BII in the US

Objectives: To update the audience on latest research in BII as well as current FDA counts of SCC and ALCL with breast implants and how this is incorporated into a breast implant consult so that the patient is well educated and can make informed decisions

Introduction: The FDA is still tracking cases of BIA SCC and BIA ALCL world wide. Incidence and mortality data will be reviewed. In addition, review of 5 papers funded by ASERF published in ASJ regarding systemic symptoms with breast implants will be reviewed

Materials / method: Review of FDA website data and its implications. Review of the four papers on SSBI (BII) in the 150 patient initial study as well as the 100 patients in the follow up no capsulectomy study will be reviewed.

Results: The FDA still Indicates a low incidence of BIA SCC, and never found in a normal capsule. The FDA indicates there are still deaths occurring from BIA ALCL despite evidence to show a very curable disease if discovered early.

The SSBI (BII) papers found no cause for symptoms in the SSBI group as compared to the 2 control groups. Pathology, heavy metals, and microbiology were all performed on the capsules. Serum levels of various cytokines, endotoxins or other abnormalities were not found. In the BII cohort there was a significant drop off of symptoms after implant removal

Conclusion: Practioners should still watch and testfor BIA ALCL and SCC. Patients complaining of SSBI (BII) have statistically symptom improvement after implant removal despite negative causative findings regardless of whether capsule is removed or not. The only symptom that never approaches baseline is anxiety. True incidence of BIA SCC and BIA ALCL and their warning signs as well as occurrence of SSBI(BII) should be discussed with preop breast implant patients. Higher anxiety levels in those SSBI patients should be discussed, particularly in patients with preexisting anxiety.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
Si
Por favor especifique las entidades (individuo, empresa, sociedad): ASERF. The Aesthetic Foundation

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo es presentado gracias al apoyo de: ASERF

Dr Cole HOLAN

Cirujano Plástico

Estados Unidos

Otro(s) autor(es) : Arman Fijany, MD, Jorys Martinez, MD

Analyzing sentiment of breast implant illness on social media with natural language processing and deep learning

Objectives: The study aims to analyze social media posts to understand patient perceptions and emotions regarding BII and to assess the relationship between the sentiment of these posts and breast implant removal rates.

Introduction: Breast Implant Illness (BII) is identified by patients as a range of symptoms related to breast implants, with increasing public interest despite no conclusive research on causality. Social media has become a key platform for sharing patient experiences and perceptions of BII. The RoBERTa NLP model, trained on extensive social media data, offers insights into these discussions.

Materials / method: Posts mentioning BII from January 2014 to December 2023 on platform X were collected and analyzed using two NLP models: a binary sentiment model and an emotion-based model. The models categorized posts as positive or negative and identified dominant emotions. Correlations between post sentiments, emotions, and implant removal data were examined using the Pearson correlation coefficient.

Results: Out of 6,099 posts over ten years, the majority were negative (75.4%), with neutrality (35.9%) and fear (35.6%) being the most common emotions. Excluding neutral posts, fear dominated 55.5% of the discourse. A strong positive correlation (r > 0.80) was found between negative, neutral, and fear posts and the rates of implant removal.

Conclusion: The analysis reveals that discussions on BII are mainly negative, with a significant focus on fear, which correlates with the increase in breast implant removals. This highlights the role of NLP in understanding patient sentiments and aiding healthcare providers in addressing patient concerns.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Dr Isabelle PLUVY

Cirujano Plástico

Francia

Otro(s) autor(es) : I Brigaud, E Randrianaridera, M Melin, F Gindraux, K Anselme

Breast implant silicone exposure induces immunogenic response and autoimmune markers in human periprosthetic tissue

Objectives: We present a pilot study investigating the inflammatory characteristics of human periprosthetic tissue following silicone exposure. In particular, we focus on changes in (i) tissue organization and (ii) transcriptomic signatures of human periprosthetic tissues exposed to different sources of silicone with respect to implant integrity (intact or ruptured), surface texturing (macro- or microtexturing) and implant filling (silicone gel or serum). This work provides new insights into the immunological mechanisms triggered by silicone, and, once again, challenges the concept of silicone safety.

Introduction: Silicone-based breast implants are commonly used, but there are concerns about theirlong-term safety. While implantation results in the formation of a periprosthetic tissue that isolates the implant from the rest of the host body, silicone can leak and reach surrounding tissues.

Materials / method: We combined histological analysis and gene expression profiling (RNA sequencing) of samples from human patients with silicone breast implants with different fillers (silicone or serum), surface topographies and/or shell rupture, and performed systematic cross-comparisons.

Results: Our study shows that exposure to silicone gel filler, even in clinically asymptomatic cases, induces an immune response. This response includes the expression of markers associated with various autoimmune diseases. We found an upregulation in the expression of genes encoding metalloproteinases (mmp1 and mmp9), onco-inflammatory markers (tnfsf13) and other genes associated with chronic inflammation such as il18, nlrc4, blnk or pycard and tnsfs14, both previously identified as diagnostic markers for rheumatoid arthritis.

Conclusion: This study provides the first biological evidence of an association between
silicone implants and autoimmune markers, highlighting the need for further research and stricter implant safety regulations. We suggest that implant design factors, such as filler type and surface texture, may influence the inflammatory response. Re-evaluation of existing clinical trials is warranted to investigate the association between implant characteristics and potential health risks.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
Si
Por favor especifique las entidades (individuo, empresa, sociedad): Agence Nationale de la Recherche ANR “Safe-implant” (ANR-22-CE19-0028-01)

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo es presentado gracias al apoyo de: Agence Nationale de la Recherche ANR “Safe-implant” (ANR-22-CE19-0028-01)

Discussion and Q&A

¿Tiene una pregunta?

Encuentre las respuestas rápidamente en nuestra sección de FAQ.

Congresos

IMCAS Americas
IMCAS Asia
IMCAS China
IMCAS World Congress

Acerca de

Empresa
Política de Confidencialidad
Mención legal

Academy

Inicio
Cursos
Webinars
Explorar
Blog

Subvenciones

Subvención educativa

Ponerse en contacto

Contáctenos

Nombre de usuario/Email

Contraseña

Mantenerme conectado

Iniciar sesión

Olvidé mi contraseña ? Todavía no tiene una cuenta? Inscríbase ahora

Mantenerme conectado

academy.Do_not_have_an_account_yet Inscríbase ahora

IMCAS World Congress 2025 Programa

BIA diseases: Myth or reality

Moderadores

Las presentaciones

Sesiones recomendadas

IMCAS World Congress 2025
Programa